At The Box Office: ‘Murderbot'
COLCHESTER, Vt. (ABC22/FOX44) – This week on 'At The Box Office' film critic Julia Swift talked about 'Murderbot', a series that follows a security robot in space as it gains free will and learns more about itself.
Despite the name, this series was a 'fun and light' watch for Swift. She notes that the show is about 'a robot who can murder, but who chooses to save people instead.'
While the show has violent moments, they appear more goofy than gory and disturbing. The setting of this other world, particularly with characters attempting to start a hippie commune, also adds to the less-violent 'vibes' of the series.
At The Box Office: 'Luz'
This series has some other great elements. Swift specifically highlights the relationships this titular robot creates with the cast.
'It's a really wonderful relationship that we see develop between him and these characters.'
Swift's biggest critique, though, is the pacing. Watchers just have to give the story some time to grow.
Still, anyone interested in watching 'Murderbots' can check it out on AppleTV+.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
an hour ago
- Buzz Feed
Really Hard TV/Film Production Quiz
I spent more than ten years working in TV production, and it was a crash course in how the film industry works. For someone who didn't go to school for it, every day was a learning experience with different pieces of equipment, terminology, and knowing set hierarchy. And after watching The Studio on Apple TV+ it got me thinking, how much does the general population know about production? So all you gotta do is answer the multiple-choice questions and let me know how you did! Action! BONUS QUESTION: Now that we know what a "multi-cam" series is, how many can you name? Let me know in the comments. I'll start: That '70s Show... And make sure you follow BuzzFeed Canada on Instagram and TikTok where you can see some of my production skills at work!
Yahoo
an hour ago
- Yahoo
0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions
GRAND RAPIDS, Mich., June 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that new preclinical data combining lead candidate 0602K and tirzepatide as a late-breaking poster will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20–23, 2025, at McCormick Place Convention Center in Chicago, Illinois. Presentation details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla, M. Abdul-Ghani, L. Norton, R.A. DeFronzo,J.R. Colca, K.S. McCommis Date & Time: Sunday, June 22, 2025, at 12:30 AM CT Location: Poster Hall (Hall F1) The abstract for this late-breaking poster will be available beginning Friday, June 20, 2025 at 6:30 PM CT. About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. Preclinical studies also demonstrate increased lean muscle mass and function, together with marked metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), including increased brown adipose tissue ("brown fat"). Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other diseases. View original content to download multimedia: SOURCE Cirius Therapeutics
Yahoo
2 hours ago
- Yahoo
‘Slow Horses' Season 5 Gets Fall Premiere Date On Apple TV+; First Look Photos Show Nick Mohammed In Guest Role
Slow Horses will return to Apple TV+ for Season 5 this fall. The streamer revealed Tuesday that the fifth installment of the espionage drama will debut with the first two episodes on September 24, followed by one episode weekly until October 22. Luckily, there's already a Season 6 incoming, too, as the series was renewed in October. More from Deadline 2025 Premiere Dates For New & Returning Series On Broadcast, Cable & Streaming 'Slow Horses' Renewed For Season 6 By Apple TV+ 'Stranger Things': Netflix Reveals Premiere Date For Season 5, Split Into Three Volumes Along with the premiere date, Apple TV+ also gave a glimpse at the new season in a series of photos. They don't give away much, but there is a glimpse of Nick Mohammed will also guest star in Season 5. See those below. Slow Horses is a darkly humorous espionage drama that follows a dysfunctional team of British intelligence agents who serve in a dumping ground department of MI5 known unaffectionately as Slough House. Gary Oldman stars as Jackson Lamb, the brilliant but cantankerous leader of the spies, who end up in Slough House due to their career-ending mistakes as they frequently find themselves blundering around the smoke and mirrors of the espionage world. In Season 5, everyone is suspicious when resident tech nerd Roddy Ho has a glamorous new girlfriend, but when a series of increasingly bizarre events occur across the city, it falls to the Slow Horses to work out how everything is connected. After all, Lamb knows that in the world of espionage, the London Rules — cover your back — always apply. The cast also includes Kristin Scott Thomas, Jack Lowden, Saskia Reeves, Rosalind Eleazar, Christopher Chung, Aimee-Ffion Edwards, Ruth Bradley, James Callis, Tom Brooke, and Jonathan Pryce. Slow Horses is produced for Apple TV+ by Heartstopper maker See-Saw Films, with Jamie Laurenson, Hakan Kousetta, Julian Stevens, Iain Canning, Emile Sherman, Adam Randall, Gail Mutrux, Douglas Urbanski and Oldman serving as executive producers. Saul Metzstein, who earned an Emmy nomination for Season 3, returns to helm Season 5. Best of Deadline 2025 TV Series Renewals: Photo Gallery 2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More Everything We Know About 'Nobody Wants This' Season 2 So Far
